Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Guinness Asset Management LTD

Guinness Asset Management LTD lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 71,763 shares of the medical research company's stock after buying an additional 12,874 shares during the period. Guinness Asset Management LTD's holdings in Thermo Fisher Scientific were worth $37,331,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Investment Solutions LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $26,000. Peterson Financial Group Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $27,000. RPg Family Wealth Advisory LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at approximately $50,000. Decker Retirement Planning Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $43,000. Finally, HWG Holdings LP purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $50,000. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on TMO. Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Bernstein Bank lifted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Stephens assumed coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 target price on the stock. Finally, Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a "buy" rating and a $680.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the sale, the chief executive officer now directly owns 111,192 shares of the company's stock, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company's stock, valued at $9,333,946.08. The trade was a 1.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Down 0.4 %

Thermo Fisher Scientific stock traded down $1.99 during mid-day trading on Monday, reaching $559.72. 2,134,669 shares of the company were exchanged, compared to its average volume of 1,426,114. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The business has a fifty day moving average of $529.96 and a 200 day moving average of $568.56. The firm has a market cap of $214.09 billion, a P/E ratio of 35.09, a PEG ratio of 3.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the company posted $5.69 earnings per share. The firm's revenue was up .2% on a year-over-year basis. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.